Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

2.870 +0.070 (+2.50%)
Streaming Delayed Price Updated: 3:46 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 Next >
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present in Upcoming June Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to... 
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
From Vigil Neuroscience, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.